Trial Profile
A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Ibrutinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 13 Feb 2024 Planned End Date changed from 30 Dec 2023 to 31 Mar 2024.
- 25 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 20 Jun 2023 Study design is changed from single-group assignment to sequential, one more treatment arm is added and timeline for primary end-point is decreased from 2 years to 8 months.